Want to see LFWD full AI Analyst Report?
Top Page
Lifeward
(NASDAQ:LFWD)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.50
▼(-26.57% Downside)
Action:Reiterated
Date:09/13/26
The score is held down primarily by weak financial performance—very large losses and ongoing cash burn despite meaningful revenue growth and improved leverage. Technicals also lean bearish with the stock trading below major moving averages and a negative MACD. Corporate events provide some strategic positives, but the financing structure also reinforces dilution/financing risk, while valuation is constrained by negative earnings and no dividend support.
Positive Factors
Revenue growth
The company has expanded revenue from roughly $6.0M in 2021 to about $21.8M TTM, while reporting 16% year-over-year Q2 growth. This indicates increasing adoption of its mobility solutions and provides a broader base for operating leverage if scale improves.
Negative Factors
Severe operating losses
Very large losses relative to revenue show that the current cost structure is not scaling with sales. The widening TTM net loss despite relatively stable revenue limits internal reinvestment capacity and makes sustained profitability dependent on substantial operating improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth
The company has expanded revenue from roughly $6.0M in 2021 to about $21.8M TTM, while reporting 16% year-over-year Q2 growth. This indicates increasing adoption of its mobility solutions and provides a broader base for operating leverage if scale improves.
Read all positive factors
Lifeward (LFWD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.57M
Dividend YieldN/A
Average Volume (3M)4.75K
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth-10.68%
EPS Growth55.33%
CountryUS
Employees81
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-16.82
Shares Outstanding2,832,016
10 Day Avg. Volume4,877
30 Day Avg. Volume4,755
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)9.55
Price to Sales (P/S)3.64
P/FCF Ratio-4.77
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue1.06
Enterprise Value/Gross Profit2.94
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$10.00Price Target Upside33.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.65
Revenue Forecast (FY)$28.78M
Lifeward Business Overview & Revenue Model
Company Description
Lifeward Ltd. is a healthcare technology company specializing in the creation, development, and commercialization of wearable robotic exoskeletons. These sophisticated devices are engineered to restore lower limb mobility for individuals living wi...
How the Company Makes Money
Lifeward makes money primarily by selling its robotic-assisted mobility products and associated support offerings. Key revenue streams include: (1) Product sales of exoskeleton systems (notably the ReWalk platform) to rehabilitation hospitals/clin...
Lifeward Earnings Call Summary
Earnings Call Date:May 15, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Nov 17, 2026
Earnings Call Sentiment Neutral
Balanced mix of strategic, financial and operational positives (acquisitions, stronger cash position, ReWalk growth, cost reductions and reduced cash burn) offset by meaningful near-term operational headwinds (22% revenue decline, 800 bps gross margin compression, increased GAAP loss and manufacturing/supply chain disruptions). Management expects to resolve AlterG timing issues across Q2–Q3, sees a path to profitability and holds revenue expectation similar to prior year but retains execution risk during the transition.Positive Updates
Strategic Acquisition of Oratech
Completed equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin expected to start Phase II). Transaction described as capital-efficient with minimal near-term operational burden and no material increase in operating expenses.
Negative Updates
Quarterly Revenue Decline
Total revenue for Q1 2026 was $3.9 million vs. $5.0 million in Q1 2025, a decline of approximately 22%, primarily due to reduced AlterG shipments from temporary supply chain and working capital constraints.
Read all updates
Q1-2026 Updates
Positive
Negative
Strategic Acquisition of Oratech
Completed equity-based acquisition of Oratech, gaining a protein oral delivery platform (including ORMD-0801 oral insulin expected to start Phase II). Transaction described as capital-efficient with minimal near-term operational burden and no material increase in operating expenses.
Read all positive updates
Company Guidance
Management did not raise formal 2026 guidance but reiterated they expect full‑year revenue to be similar to 2025, with the Q1 shortfall ($3.9M vs. $5.0M in Q1‑2025) to be largely made up across Q2–Q3 as AlterG backlog ships (potentially resolved by Q3); they highlighted ReWalk revenue up 11% YoY to $1.6M, gross margin down to 34.2% from 42.2% (~800 bps, 75–85% due to FX and tariffs and the rest from lower absorption), total operating expenses of $11.7M (including a ~$4.9M one‑time noncash R&D charge), adjusted Opex down 12% to $5.9M (from $6.8M), GAAP operating loss of $10.3M and unchanged adjusted operating loss of $4.6M, cash used in operations down 33% to $3.7M, and liquidity improved to $11.4M unrestricted cash (vs. $2.2M at YE‑2025) after a $10M convertible financing and ~ $6.5M cash from the Oratech acquisition, positioning the company for operational stabilization and a clearer path to profitability into late 2026/2027.Lifeward Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.82M | 22.03M | 25.66M | 13.85M | 5.51M | 5.97M |
| Gross Profit | 7.85M | 8.43M | 8.22M | 4.45M | 1.91M | 2.90M |
| EBITDA | -24.40M | -19.34M | -24.93M | -20.28M | -18.90M | -12.39M |
| Net Income | -30.83M | -19.91M | -28.94M | -22.13M | -19.57M | -12.74M |
Balance Sheet | ||||||
| Total Assets | 35.00M | 22.90M | 30.49M | 63.19M | 74.24M | 94.75M |
| Cash, Cash Equivalents and Short-Term Investments | 9.45M | 2.17M | 6.94M | 28.08M | 67.90M | 88.34M |
| Total Debt | 11.07M | 4.39M | 880.00K | 1.90M | 897.00K | 1.06M |
| Total Liabilities | 22.78M | 14.49M | 11.64M | 16.68M | 6.07M | 5.37M |
| Stockholders Equity | 12.22M | 8.41M | 18.85M | 46.51M | 68.17M | 89.38M |
Cash Flow | ||||||
| Free Cash Flow | -17.09M | -16.83M | -21.72M | -20.75M | -17.92M | -11.52M |
| Operating Cash Flow | -17.08M | -16.83M | -21.72M | -20.67M | -17.89M | -11.47M |
| Investing Cash Flow | 6.46M | -16.00K | 0.00 | -18.15M | -25.00K | -47.00K |
| Financing Cash Flow | 14.93M | 12.20M | 0.00 | -992.00K | -2.50M | 79.51M |
Lifeward Technical Analysis
Negative
7.49
Price Trends
7.17
Negative
7.24
Negative
7.12
Negative
Market Momentum
-0.26
Positive
21.26
Positive
26.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LFWD, the sentiment is Negative. The current price of 7.49 is above the 20-day moving average (MA) of 6.90, above the 50-day MA of 7.17, and above the 200-day MA of 7.12, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 21.26 is Positive, neither overbought nor oversold. The STOCH value of 26.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LFWD.
Lifeward Risk Analysis
Lifeward disclosed 43 risk factors in its most recent earnings report. Lifeward reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lifeward Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $51.46M | -1.48 | 1248.13% | ― | 6.09% | 30.65% | |
47 Neutral | $10.20M | -1.22 | -126.45% | ― | -1.67% | 7.34% | |
45 Neutral | $16.57M | -0.40 | -310.86% | ― | -10.68% | 55.33% | |
45 Neutral | $12.76M | -0.69 | -445.14% | ― | 8.64% | -61.01% | |
44 Neutral | $28.94M | -1.17 | -79.21% | ― | 53.42% | 22.08% | |
43 Neutral | $11.30M | -3.39 | -78.94% | ― | 3.68% | 36.91% |
* Healthcare Sector Average
LFWD
Lifeward
6.67
-2.95
-30.65%
IRIX
Iridex
0.69
-0.44
-38.94%
NSPR
InspireMD
0.58
-1.92
-76.80%
CTSO
Cytosorbents
3.97
-14.84
-78.91%
NMTC
NeuroOne Medical Technologies
1.12
-4.86
-81.33%
TELA
TELA Bio
1.14
-0.38
-25.00%
Lifeward Corporate Events
Executive/Board Changes
Lifeward Announces Interim CFO Leadership Transition Phase
Neutral
Oct 1, 2026
On September 30, 2026, Lifeward Ltd. completed the previously announced transition of its Chief Financial Officer role with the departure of Almog Adar as CFO, principal financial officer, and principal accounting officer. Effective October 1, 202...
Regulatory Filings and ComplianceShareholder Meetings
Lifeward Sets Timeline for 2026 Shareholder Meeting
Neutral
Sep 15, 2026
Lifeward Ltd. has scheduled its 2026 Annual and Extraordinary General Meeting of Shareholders for October 30, 2026, marking a meeting date set more than 30 days after the anniversary of its 2025 annual general meeting. The board has outlined the t...
Business Operations and StrategyFinancial Disclosures
Lifeward Highlights Growth Strategy in New Investor Presentation
Positive
Sep 8, 2026
On September 8, 2026, Lifeward posted a new investor presentation outlining its investment thesis and growth strategy, underscoring a commercial platform built around robotics, AI and reimbursement to restore motion and independence for patients w...
Business Operations and StrategyExecutive/Board Changes
Lifeward Announces Major CEO and CFO Leadership Changes
Neutral
Aug 31, 2026
Lifeward Ltd. underwent significant leadership changes on August 31, 2026, when President and Chief Executive Officer Mark Grant departed from his executive roles and board seat under a separation agreement that ended future equity vesting and pro...
Business Operations and StrategyPrivate Placements and Financing
Lifeward Announces New Convertible Notes and Warrants Financing
Positive
Jul 7, 2026
On June 30, 2026, Lifeward entered into amended and restated senior secured convertible notes, common warrants, and pre-funded warrants with Oramed Pharmaceuticals Inc. and certain investors, revising pari passu treatment, mandatory redemption, an...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.